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Autosomal dominant hyperuricemia, gout, renal cysts, and
progressive renal insufficiency are hallmarks of a disease
complex comprising familial juvenile hyperuricemic
nephropathy and medullary cystic kidney diseases type 1 and
type 2. In some families the disease is associated with
mutations of the gene coding for uromodulin, but the link
between the genetic heterogeneity and mechanism(s)
leading to the common phenotype symptoms is not clear. In
19 families, we investigated relevant biochemical parameters,
performed linkage analysis to known disease loci, sequenced
uromodulin gene, expressed and characterized mutant
uromodulin proteins, and performed immunohistochemical
and electronoptical investigation in kidney tissues. We
proved genetic heterogeneity of the disease. Uromodulin
mutations were identified in six families. Expressed, mutant
proteins showed distinct glycosylation patterns, impaired
intracellular trafficking, and decreased ability to be exposed
on the plasma membrane, which corresponded with the
observations in the patient’s kidney tissue. We found a
reduction in urinary uromodulin excretion as a common
feature shared by almost all of the families. This was
associated with case-specific differences in the uromodulin
immunohistochemical staining patterns in kidney. Our results
suggest that various genetic defects interfere with
uromodulin biology, which could lead to the development of
the common disease phenotype. ‘Uromodulin-associated
kidney diseases’ may be thus a more appropriate term for
this syndrome.
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Familial juvenile hyperuricemic nephropathy (FJHN)
(OMIM 162000),1,2 and medullary cystic kidney diseases
type 1 (MCKD1; OMIM 174000),3 and type 2 (MCKD2;
OMIM 603860)4 are autosomal dominant tubulointerstitial
nephropathies characterized by combinations of hyperurice-
mia, gouty arthritis, progressive renal insufficiency, and in
some but not all families, medullary cysts. Recently it was
found that in some families FJHN and MCKD2 are allelic
disorders associated with mutations of the uromodulin gene
(UMOD) coding for uromodulin (UMOD), Tamm–Horsfall
protein.5–12 However, UMOD mutations are not the only
cause of the FJHN/MCKD phenotype,8,9 which confirmed
the broader genetic heterogeneity suggested by linkage
studies.13–18 The other candidate loci for FJHN/MCKD were
identified on chromosome 1q21,18–21 chromosome 1q41,22
and a disease causing mutation in HNF-1b gene was found
in a single family with features of FJHN and diabetes.23 The
mechanism linking the genetic heterogeneity to common
disease symptom development in families with no UMOD
mutations is not clear but it was suggested that UMOD
dysfunction might be a common pathogenic mechanism.22
In this study, we have investigated 19 families showing
characteristics of the FJHN/MCKD phenotype. In all families
we performed linkage analysis to all known FJHN/
MCKD loci, and analyzed the UMOD genomic sequence.
Disease causing UMOD mutations were identified in only six
families. We transiently expressed mutant proteins in
eucaryotic cells and correlated its properties with biochem-
ical, immunohistochemical, electron microscopy observa-
tions and specific disease symptoms. We also found that
decreased urinary UMOD excretion is common to almost all
patients independent of their corresponding linkage groups.
The changes in urinary UMOD excretion were accompanied
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by case-specific differences of UMOD immunohistochemical
staining patterns in kidney tissues.
Our work suggests that various genetic defects and
mechanisms hamper UMOD biology, which lead to the
development of the FJHN/MCKD phenotype, and this lends
support to the term of ‘uromodulin-associated kidney
diseases’ (UAKD)5,22 as a more appropriate for the FJHN/
MCKD syndrome.
RESULTS
Clinical and biochemical findings
The pedigrees of families not yet reported are shown in
Figure 1.
The family CZ4 came to attention through the probands
N IV.3 (39 years old), and N IV.4 (31 years old), who suffered
from gout. Biochemical investigation showed hyperuricemia,
reduced fractional excretion of uric acid, and elevated
concentration of plasma creatinine. Urinary UMOD excre-
tion was absent. Their father N III.3 (62 years old) suffered
from gout, which appeared for the first time at 23 years of
age. He gradually developed renal insufficiency, which was
treated at 55 years of age by dialysis and two years later by
renal transplantation.
The family CZ5 came to attention through the proband F
II.1 who suffered from gout, which appeared for the first time
at 26 years of age. Biochemical investigation showed hyperur-
icemia (over 700mmol/l), reduced fractional excretion of uric
acid (5.9%), and elevated concentration of plasma creatinine
(204mmol/l). Following treatment with allopurinol, uricemia
normalized, but the gouty attacks have persisted and patient
(now 36 years old) has developed hypertension and chronic
renal insufficiency. Sonography showed bilateral small kidneys
with reduced parenchyma and single cyst (5 mm). Urinary
UMOD excretion was absent. Molecular investigation revealed
a pathogenic mutation resulting in C32Y substitution in
UMOD protein. All the relatives have been reported healthy,
their biochemical investigations showed no abnormalities,
molecular investigation has not revealed in any of them the
presence of pathogenic UMOD mutation. The possibility of
nonpaternity was excluded by STR analysis.
The family US1 came to attention through the proband US
I.1., who developed gout during pregnancy at the age of 27
years. Biochemical investigation showed hyperuricemia which
did not responded to any treatment, reduced fractional
excretion of uric acid and elevated concentration of plasma
creatinine (185mmol/l). Sonography showed small kidneys and
renal biopsy revealed glomerular sclerosis and glomerular cysts.
Individuals US II.1 (23 years old) and US II.2 (21 years old)
showed hyperuricemia (4700mmol/l), elevated concentration
of plasma creatinine (4200mmol/l), and urea (47.5 mmol/l).
Both patients responded to allopurinol and had no further gout.
No urine was available for investigation of UMOD excretion.
The other families have been described pre-
viously.13,15,18,24,25 The diagnosis of FJHN/MCKD was based
on the familial occurrence of chronic renal disease associated
with or preceded by early onset of hyperuricemia associated
with reduced fractional excretion of uric acid o5%.
Biochemical investigations showed no notable abnormalities
in other serum ion concentration. Urine biochemical
parameters measured in available individuals are shown in
Table 1. Clinical information on individuals with UMOD
mutations is provided in Table 2.
Genotyping and linkage analysis
Linkage analyses to the UMOD candidate locus in 16 families
have been reported previously.13,15 Families US1, CZ4, and CZ5
are reported here for the first time. As summarized in Table 3,
the genetic linkage to the UMOD candidate locus on
chromosome 16p11.2 was found in nine of the analyzed families
and excluded, based on the logarithm of odds (LOD)¼2
criterion, in three families. A single family BE1 has been linked
to UAKD locus on 1q41 previously22 and in family GB4, a
disease-causing mutation in HNF-1b gene was found.23 In the
rest of the families, no consistent haplotypes segregating with
any of the currently known FJHN/MCKD loci were found.
UMOD gene analysis
Sequence analysis revealed missense mutations in six families
(Table 3, Figure 2) and several novel single-nucleotide
polymorphisms (Table 4). In families, which showed genetic
linkage to the UMOD candidate locus on chromosome
16p11.2, and in which no UMOD mutation was identified,
the 5.7-kb promoter sequence of the UMOD gene was also
analyzed. Identified nucleotide changes are shown in Table 4.
Transient expression of UMOD
We cloned wild type and identified mutated UMOD cDNA
sequences into mammalian expression vector and transiently
expressed wt-UMOD protein in HEK-293, MDCK, CHO, and
AtT-20 cells. The UMOD processing and localization patterns
were essentially identical in all the cell lines (data not shown).26
AtT-20 cells were chosen for further experiments as they were the
most easy to culture, showed higher transfection efficiency, and
performed best with available compartment markers antibodies.
Flow cytometry
The amount of the UMOD expressed on the plasma
membrane was measured 6, 12, 18, and 24 h after transfection
CZ4 CZ5 USI
N II.1 N II.2 F I.1
F II.1 F II.2 F II.3 F II.4 US II.1 US II.2
F III.1
F I.2 US I.1
N III.2 N III.3 N III.4
N IV.2 N IV.3 N IV.4
N III.1
N IV.1
Figure 1 | Pedigree diagram of the investigated and not yet
reported UAKD families. Black symbols denote affected individuals,
open symbols denote unaffected individuals.
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Table 1 | Urine biochemical parameters measured in patients with mutation in UMOD gene (UMOD+), in patients with no
mutation in UMOD gene (UMOD), and in controls
Parameter UMOD+ (n) P UMOD (n) P Control (n=77)
Age 40718 (21) NS 40716 (11) NS 36713
Creatinine (mmol/l) 6.573.2 (16) NS 7.874.7 (31) NS 9.075.4
Na/Cr (mmol/mmol) 13.977.9 (16) NS 12.478.0 (31) NS 13.978.8
K/Cr (mmol/mmol) 4.9371.74 (16) NS 4.4572.18 (31) p0.05 6.5474.30
Mg2+/Cr (mmol/mmol) 0.3070.11 (14) NS 0.2970.18 (24) NS 0.3770.27
PO4/Cr (mmol/mmol) 1.8070.67 (14) NS 2.0171.27 (24) NS 1.9671.22
Cl/Cr (mmol/mmol) 12.377.5 (16) NS 10.676.7 (31) p0.01 17.2711.6
Ca2+/Cr (mmol/mmol) 0.1970.19 (14) p0.05 0.1070.10 (24) p0.0001 0.3570.25
Osmolality (mOsm/kg) 329765 (14) p0.01 414788 (13) p0.05 5727278
UCB/Cr (mg/mmol) 697167 (16) p0.001 30747 (31) p0.001 8.578.7
UA/Cr (mmol/mol) 103781 (14) p0.0001 120790 (24) p0.0001 2477109
Umod/Cr (mg/g) 1.875.5 (14) p0.0001 9.1714.7 (32) p0.0001 35.7717.8
Values are reported as means7s.d.; P-values (t-test) correspond to the comparisons between the corresponding group and controls.
Cr, creatinine; NS, not significant; UA, uric acid; UCB, total protein.
Table 2 | Clinical information on individuals and families in which UMOD mutations were identified
Family (ID) Sex/age
Age of
onset
First
symptoms
Blood
pressure Gout Cr UA
Renal
ultrasound Present status
Family CZ1, kindred A in Stiburkova et al13
AI2 F/w 30y Gout +/? +/30y +/? +/? SK/single C TR 58y; w63y
AII3 F/52y 18y Gout +/25y +/18y +/18y +18y SK, no C RKF, arthritis
AII5 M/55y 20y Gout +/40y +/20y +/20y +20y SK, no C TR 54y, no problems
AIII2 F/22y 6ya HU +/17y No +/6y +/6y SK, no C No problems
AIII3 M/25y 12ya HT +/12y No +/12y +/6y Normal RKF
Family CZ2, kindred B in Stiburkova et al13
BI2 F/w NA NA NA NA NA NA NA RF/w49y
BI3 M/w NA NA NA +/? NA NA NA RF/w56y
BII1 M/39y 26y Gout NA +/26y +/31 +/26y NA RKF
BII2 M/53y 20y Gout, HU +/40y +/20y +/25y +/20y SK/multiple C RKF
BII6 M/55y 17y Gout +/25y +/? +/20y +/20y NA RF, TR 28y, 42y
BII9 F/53y 20y HT +/? +/30y +/23y +/25y SK/multiple C RF, TR 43y
BIII1 F/31y 17y Gout +/23y +/17y +/17y +/17y SK/single C RKF
BIII2 M/28y 15ya FH No No +/22y +/15y Normal No problems
BIII3 F/27y 10ya FH +/25y +/10y +/10y +/10y Normal No problems
BIII7 F/29y 24ya FH +/29y No +/26y +/24y Normal HT
Family CZ5 (this report)
II1 F/36y 26y Gout +/28y +/26y +/26y +/26y Normal HT, obesity
Family BE 2, (15)
EII3 M/68y 20y Albuminuria NA +/30y +/30y +/30y NA TR 65y, no problems
EII4 M/62y 20y Gout NA +/20y +/20y +/20y NA 60y, hemodialysis
EII5 M/NA 40y Gout NA +/40y +/40y +/40y NA NA
Family GB225
C4 F/w 31y Gout +/31y +/31y +/31y +/31y NA TR; w36y
C1 F/43y 19ya HU No No No No No No problems
C2 M/40y 16ya HU No No No No No No problems
Family GB7, kindred 6 in McBride et al24
L7 F NA HU NA +/? NA NA NA RF
L4 F NA HU NA +/? NA NA NA NA
L12 F NA HU NA NA NA NA NA NA
L10 F/w 15y Gout +/25y +/15y NA NA NA Dialysis; w63y
L15 M NA HU NA NA NA NA NA NA
aOr when the first signs of the disease were recognized; +/y, + the symptom is present/age of onset.
C, renal cysts; Cr, serum (plasma) creatinine; FH, family history; HU, hyperuricemia; HT, hypertension; NA, not available; RF, renal failure; RKF, reduced kidney function; SK, small
kidney size; TR, kidney transplantation; UA, serum (plasma) uric acid; UMOD, uromodulin; y, years.
wDied.
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(Figure 3a). The time-course experiments showed a gradual
increase of the wild-type UMOD protein expressed on
plasma membrane with a plateau being reached in 18–24 h.
Mutant proteins – 32Y, 229R, and 317Y (group I mutants) –
showed patterns similar to the wild-type protein but the
amount of protein localized on the plasma membrane was
always lower as compared to the wild-type protein. The other
mutant proteins – 126R, 236L, and 273F (group II mutants)
showed a poor ability to reach the plasma membrane as
compared to both, wild-type protein and group I mutants.
The differences were statistically significant when measured
18 h post-transfection (Figure 3b).
SDS-PAGE and Western blot analysis
UMOD protein was analyzed in cell lyzates and medium
(Figure 4). Wild-type protein was present in two 85 and
71 kDa zones (Figure 4a) as observed previously.26 Both
zones were smeared as they were probably composed of
several poorly resolved bands corresponding to hetero-
geneous oligosaccharide processing of UMOD.27 Complex
deglycosylation treatment with peptide N-glycosidase F
(PNGase F, Figure 4c), sialidase A (Figure 4e), and endo-O-
glycosidase (Figure 4b) showed that both zones represent
different UMOD glycoforms. The 85 kDa zone represents
properly glycosylated, glycosyl-phosphatidylinositol (GPI)-
modified and membrane-anchored UMOD protein as it
corresponds to that of the molecular weight of UMOD
excreted in urine. The 71 kDa zone represents a UMOD
precursor probably lacking branched sialic acids and terminal
sialic acid residues as its molecular weight corresponds to
that of the 71 kDa zone appearing after the treatment of
the urinary and recombinant wt-UMOD with sialidase
A (Figure 4e). This 71 kDa UMOD precursor probably
accumulates owing to protein overexpression, as it is not
markedly observed in a stable UMOD-expressing cell line
(Figure 4f), and probably represents a protein intermediate
along the secretory pathway. No detectable effect on the wild-
type mobility was observed after endo-O-glycosidase treat-
ment (Figure 4b), which suggests that either no significant
O-glycosylation of UMOD occurs in AtT-20 cells, or that the
action of the enzyme is blocked by extended modification of
the core structure by other saccharides.28 In agreement with
Rindler et al.,26 neither wild-type and later nor any
of the mutant UMOD proteins were detected in medium
of cultured cells (data not shown).
As seen in Figure 4a, group I mutants – 32Y, 229R, and
317Y – showed similar amounts of the fully processed 85 kDa
form as the wild-type protein. The 229R mutant differed
from the other two by the absence of 71 kDa form and the
appearance of a 69 kDa band, which probably corresponds to
the endoplasmic reticulum (ER)-retained intermediate lack-
ing GPI anchor (see below) and missing Golgi-mediated
glycosylation trimming. Group II mutants showed low
amounts of the fully processed 85 kDa form and retention
of the 69 kDa intermediate protein.
Following the treatment of expressed proteins with
PNGase F (Figure 4c), the group I mutants as well as the
wild-type protein appeared in two 57 and 52 kDa forms
which represent, respectively, the protein precursor and the
protein with cleaved C-terminal ecto-domain and covalently
linked GPI anchor. Observed incomplete processing may be
attributed to protein overexpression as reported pre-
viously.29,30 GPI anchor attachment was less pronounced in
the 229R mutant and no precursor processing and GPI
linkage was observed in group II mutants.
Treatment with sialidase A (Figure 4e) showed that two
proteins from group I mutants – 32Y and 317Y – as well as the
wild-type protein sialidase A were sensitive and corresponded
to a single zone of B71 kDa. Partial resistance to sialidase
treatment was observed in the 229 R and 236L mutants,
which produced two zones of 71 and 65 kDa. Other group II
mutants showed the original 71 kDa zone and the processed
form of 62 kDa.
Complex deglycosylation with a mixture of all three
enzymes (Figure 4d) showed comparable results as for the
PNGase F treatment (Figure 4c).
Immunofluorescence
Images of the individual UMOD proteins are shown in
Figure 5. The wild-type protein localized on the plasma
membrane, with almost no detectable intracellular retention.
All the mutant proteins showed granular retention of UMOD
in the ER. The ER retention was less pronounced in group I
Table 3 | Summary of linkage analysis to all of currently
known FJHN/MCKD loci with results of UMOD sequence
analysis
Family
UMOD
16p11.2
UMOD
mutation
MCKD1
1q21
UAKD
1q41
CZ1 + C317Y ND ND
CZ2 + M229R ND ND
CZ3 Ex No Ex Ex
BE1 Ex No Ex +
BE2 + V273F ND ND
GB1  No Ex 
GB2 + C126R ND Ex
GB3 + No  
GB4a Ex ND ND Ex
GB5  No  Ex
GB6  No  
GB7 /+b P236L ND ND
GB8 + No ND 
GB9  No  
GB10  No  
MCKD6  No  
CZ4 + No  
CZ5 ND C32Y ND ND
US1 + No  
Ex, families excluded for linkage on LOD p2 criterion; +, Families segregating
haplotypes consistent with linkage; , Families with haplotypes inconsistent with
linkage. ND, not done.
aFamily GB4 with a disease-causing mutation in HNF-1b gene.
bChanging the original status in person L11 (GB7) to healthy, the LOD for that family
goes up from 0.49 (before) to 1.47 (now) and the haplotypes are consistent with
linkage.
FJHN, familial juvenile hyperuricemic nephropathy; LOD, Logarithm of odds; MCKD,
medullary cystic kidney diseases; ND, not done; UMOD, uromodulin.
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mutant proteins, which also showed strong presence on the
plasma membrane. The group II mutants showed almost no
plasma membrane localization. No significant presence of the
proteins in Golgi apparatus was observed (data not shown).
Urinary UMOD analysis
UMOD excretion was investigated in spot urine collected
from 71 controls and 96 subjects originating from the 15
affected families. From the 96 subjects, 49 have been classified
as affected, based on the clinical and biochemical data
obtained. Of those 49 patients, 14 patients have the UMOD
mutation, 14 patients are from families linked to the
UMOD region on chromosome 16p11.2 but in whom
no UMOD mutations have been found, 16 patients are from
families in which a linkage has not yet been found, and four
patients are from a single family which mapped to the
region on chromosome 1q41.22 One other patient with
UMOD mutation was investigated after kidney transplanta-
tion (T). Qualitative analysis showed the absence or decrease
of urinary UMOD excretion in almost all affected indivi-
duals. Abnormal UMOD processing has been observed in
several individuals, classified as healthy and originated from
different families (Figure 6). No co-segregation of the
abnormal UMOD processing and disease phenotype has
been found.
Quantitative analysis showed that the UMOD excretion
was significantly reduced in almost all affected individuals,
independent of the linkage groups they belonged to
(Figure 7a). Analysis performed separately for each family
(Figure 7b) showed that UMOD excretion was reduced in all
families except family CZ3. Decreased UMOD excretion was
present also in young patients with relatively preserved renal
function (Figure 7c). UMOD excretion normalized in a single
patient with the UMOD mutation after kidney transplantation.
Immunohistochemistry and electron microscopy
Prominent differences in the patterns of UMOD immuno-
histochemical staining were observed in available kidney
tissues. They encompass massive intracellular UMOD
accumulation in the patients with UMOD mutation, and
presence of UMOD in hyaline casts with low intracellular
positivity, irregular pattern of UMOD staining or strongly
reduced UMOD expression in patients with not yet
established molecular defects. Patterns of UMOD staining
were correlated and mostly parallel with that of the epithelial
membrane antigen (MUC1) (Figure 8).
C32Y P236L
V273F
C317Y
C126R N128N
M229R
M P C
RsaI
M PC
FoKI
M PC
AccI
M P C
RsaI
M P C
NIaIII
M PC
NIaIII
CZ5 GB7
GB2 Be2
CZ2 CZ1
Figure 2 | UMOD mutations detected in indicated families and polymerase chain reaction-restriction fragment length polymorphism
assays employed in genotyping and mutation analysis. M: size marker standard, P: patient, C: control individual.
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Material for ultrastructural studies was available from a
single case with M229R UMOD mutation. The tubular
epithelium displayed a number of nonspecific changes such
as atrophy, hyper regeneration, and increase in dense
lysosomal residual bodies. Significant changes related to
molecular pathology of the disorder are shown and described
in Figure 9. The ER storage material has been identified as
an accumulated UMOD protein by immunofluorescence
analysis of renal biopsy tissue (Figure 10).
DISCUSSION
FJHN/MCKD is a genetically heterogeneous disease with only
a proportion of families having a demonstrable mutation in
the UMOD gene.
In this work, we characterized in more detail 19 families
fulfilling the basic clinical and biochemical criteria of FJHN/
MCKD. We completed linkage analysis to three currently
known FJHN/MCKD loci – UMOD loci on chromosome
16p11.2, MCKD1 loci on chromosome 1q21, and the UAKD
loci on chromosome 1q41. The greatest proportion, nine
families, showed linkage to the UMOD candidate region, the
rate of which is comparable with results in several other
studies.8,9,14 Linkage to the UAKD loci on chromosome 1q41
was detected in just a single family and linkage to MCKD1
was not found. Finally, no linkage to any of the above loci was
detected in eight families and in a single family, family CZ3,
all three loci were even excluded on the LOD¼2 criterion.
This result suggests that a second major or several other
FJHN/MCKD loci exist and remain to be discovered. Another
explanation for such a low detection rate might be false
negative results of linkage analysis. In the FJHN/MCKD
phenotype, this might be caused by late onset and/or reduced
penetrance of the disease,13,31 phenocopy or by co-occurrence
of the disease trait with relatively common phenotypes such
as hyperuricemia,9 gout, or the metabolic syndrome.32
However, analysis of the UMOD genomic sequence showed
the false negativity of linkage analysis only in a single family
GB7. Interestingly, UMOD mutations were found in five but
Table 4 | Nucleotide changes found in UMOD genomic
sequence
gDNA
position
Nucleotide
change Exon/intron
Protein
change dbSNP Family
UMOD promotor
5634 C-C/A
5589 G-G/A
5494 G-G/A
5316 T-T/C US1
5074 T-T/C
4893 A-A/G
4754 G-G/A
2531 T-T/C
1379 T-T/C GB3
UMOD-coding sequence
110 G-G/A Int 3
1821 C-C/T Ex 4 128Asn-Asn GB2
1959 T-T/C Ex 4 174Cys-Cys rs7193058
2061 G-G/A Ex 4 208Gln-Gln
2229 G-G/A Ex 4 264Val-Val rs13335818
2352 G-G/T Int 4
2380 T-A Int 4
2427 C-C/A Int 5 CZ3
2793 C-C/A Int 5
4662 C-C/T Int 6 rs4506906
4779 G-G/A Int 6
4805 G-G/A Int 6
9192 C-G Int 7 rs9928757 GB5
9299 T-T/C Int 7 rs9646256
9370 C-C/T Int 7
9377 C-C/A Int 7
13 540 C-C/A Int 9
aNumbering: initiation codon ATG=1.
Underline values indicate nucleotide changes observed exclusively in indicated
families.
Ex, exon; Int, intron; UMOD, uromodulin.
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Figure 3 | Fluorescence-activated cell sorter analysis of
UMOD-positive AtT-20 cells transfected with pCR3.1 eucaryotic
expression vector containing wild-type and identified mutant
UMOD cDNAs. (a) Time course showing saturation of the UMOD
plasma membrane exposition in between 18 and 24 h after the
transfection. Two groups of mutants, either showing similar dynamics
of the plasma membrane exposition as the wild-type protein but with
the final amount of the protein significantly reduced (group I
mutants, blue lines), and mutants not exposed on the plasma
membrane (group II mutants, red lines), are clearly separated.
(b) The differences in UMOD plasma membrane exposition between
wild-type UMOD (black column), group I mutants (gray columns), and
group II mutants (dashed columns) measured 18 h after transfection.
The values represent means of fluorescence 7s.d. of three
transfection experiments carried out in triplicates. The differences
between wild-type UMOD, group I mutants, and group II mutants
were statistically significant when tested by one-way analysis of
variance using Tukey’s multiple comparison procedure (Po0.001).
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not in the other four families originally linked to UMOD
candidate region on chromosome 16p11.2. This finding may
be explained by false positivity of the linkage analysis that has
arisen from the small number of investigated individuals or
indicates the existence of other disease gene located in the
UMOD candidate region. The other explanation may be
undetected mutations in UMOD promoter sequence or the
existence of synonymous exonic mutations and/or intronic
mutations affecting proper UMOD mRNA processing. We
found several such ‘private mutations’ in the promoter
sequence in families US1 and GB3 but their potential
pathogenic effect has not yet been further investigated. Overall,
only six disease-causing mutations in the UMOD gene were
identified in 19 FJHN/MCKD families. Such a low detection
rate is in agreement with at least two similar extensive
studies8,9 and further confirms the considerable degree of
genetic heterogeneity of the FJHN/MCKD phenotype.
Functional consequences of UMOD mutations
From the identified mutations, three mutations have been
already reported in other families. Mutation C126R was
found in family GB2, in Italian family F5,9 and an Austrian
family 13/00,6 which is a branch of family GB2. Mutation
C317Y was found in Czech family CZ1 and in an Italian
family MCKD no. 1.7 Mutation P236L was found in GB7 and
in the Japanese family no. 1.10 Three identified mutations,
C32Y, M229R, and V273F are novel. To prove their
pathogenity, we cloned all the mutations and characterized
transiently expressed mutant proteins. All the mutant
proteins differed from the wild-type protein in their ability
to reach the exoplasmic face of the plasma membrane
and according to it they clustered into two groups. Group I
mutants showed reduced ability and group II mutants were
not able to reach the plasma membrane. The ability of the
protein to reach the plasma membrane was determined by
GPI modification. GPI-modified proteins (group I mutants)
may exit endoplasmic reticulum, enter secretory pathway and
reach the plasma membrane. In these mutants, the associated
pathogenic mechanism may thus be related to impaired
intracellular trafficking, decreased ability of the protein to be
properly internalized and exposed on the exoplasmic face of
the plasma membrane, or defective assembly of UMOD
filaments. In contrary, mutants lacking GPI (group II
mutants) cannot exit and remain retained within ER lumen,
which leads to marked expansion of the organelle, attenua-
tion of the translation of other polypeptides, activation of the
stress signaling pathway, and progressive tissue damage.30
Both mechanisms are compatible with a concept of
autosomal dominant negative effect of the disease. In the
group I mutants, both the wild-type and misfolded mutant
protein may be trapped together in transport cargo vesicles
where their co-occurrence may delay or hamper intracellular
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Figure 4 | Western blot analyses of wild-type (WT) and individual mutated UMOD-expressing AtT-20 cell lyzates treated by
various glycosidases. Lyzates of transfected cells, (a) harvested 24 h after transfection, were treated by (b) O-glycanase, (c) PNGase F,
(e) sialidase A, and (d) mixture of PNGase F, O-glycanase, and sialidase. Panel (f) shows Western blot analysis of lyzates of stable (S) and
transiently (WT) UMOD-expressing cell lines. Uromodulin isolated from urine (U) was used as a control; þ indicates treatment and  indicates
no treatment with corresponding glycosidase. Molecular weights are given in kilodaltons on the left-hand side of the individual panels.
The molecular weight calibration curve was constructed by plotting decadic logarithm of molecular weights versus distance of
corresponding bands of the protein molecular weight marker (Precision Plus Protein Kaleidoscope Standards, Biorad) from the upper
edge of the SDS-PAGE gel after blotting. Molecular weights of different UMOD glycoforms were calculated from their distances using
logarithmic regression equation.
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trafficking process or lateral transmembrane transport as in
several other kidney diseases.33 Another alternatives might be
that the presence of the mutant protein on the cell surface
hampers proper copolymerization and assembly of UMOD
filaments,34 which then affects the proper biological func-
tion(s) of UMOD on the plasma membrane. In the group II
mutants, the disease mechanism might be different. The
mutant protein is probably retained and accumulates
gradually in the ER. The accumulation of unfolded proteins
in the ER leads to marked expansion of the organelle,
attenuation of the translation of other polypeptides, activa-
tion of the stress signaling pathway, and progressive tissue
damage.35 Two questions however remain to be answered.
First, to what extent the results of in vitro studies correlate
with the real situation in kidney tissues of affected
individuals and second, whether any particular phenotypic
patterns might be assigned to individual UMOD mutant
groups. Such a correlation might have been done only for the
mutation 229R. According to the expression studies, this
mutation seems to have both the suggested pathogenic
effects. The protein should reach to a certain extent the
plasma membrane but it should also be less efficiently GPI
modified and retained in the ER. This possibility corresponds
well with the immunohistochemistry and electron micro-
scopy investigations of the kidney tissue available from the
patient. Eventual genotype-specific phenotypic differences
cannot be judged easily since only a small number of families
and inadequate clinical data are currently available. More
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Figure 5 | Cellular localization of wild-type UMOD and individual UMOD mutants in permeabilized AtT-20 cells studied 18 h after
transfection. Columns (a, i, q, y, gg, oo, ww, l, m, u, cc, kk, ss, aaa) UMOD; columns (b, j, r, z, hh, pp, xx) PDI as a marker of ER; column
(f, n, v, dd, ll, tt, bbb) pan-Cadherin as a marker of plasma membrane. Column (c, k, s, aa, ii, qq, yy) show merged signals of individual
UMOD proteins (red fluorescence) with the markers of ER (green fluorescence). In column (d, l, t, bb, jj, rr, zz), the resulting colocalization
map of UMOD and PDI is shown. Column (g, o, w, ee, mm, uu, ccc) show merged signals of individual UMOD proteins (red fluorescence)
with the marker of plasma membrane (green fluorescence). In column (h, p, x, ff, nn, vv, ddd), the resulting colocalization map of UMOD
and pan-Cadherin is shown. Wild-type UMOD localized exclusively on the (g, h) plasma membrane, with only minor presence in the (c, d) ER.
(k, s, aa, ii, qq, yy and l, t, bb, jj, rr, zz) All the mutant proteins show retention of UMOD in the ER. The ER retention is less pronounced in
the properly GPI-modified group I mutants 32Y (k, l), and 317 Y(yy, zz), which show also strong presence on the plasma membrane
(o, p and ccc, ddd), respectively. Only partly GPI-processed 229R mutant (row y–ff), and GPI-unprocessed 126R mutant (row q–x) show irregular
plasma membrane localization (ee, ff and w, x respectively). The transport compromised group II mutants 236L (row gg–nn) and 273F
(row oo–vv) show almost no plasma membrane localization (mm, nn and uu, vv respectively).
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work in this direction is warranted since different pathogenic
mechanisms might be targeted more effectively by different
therapeutic approaches.36
Defects in UMOD biology seems to be common to the
pathogenesis of FJHN/MCKD
The link between UMOD mutations, intracellular protein
aggregation, and absence of the protein in urine has been
shown in several studies.7,9,37 However, not much informa-
tion is available on UMOD excretion in FJHN/MCKD
patients having no UMOD mutation. Analysis in a single
such family showed normal UMOD excretion9 and it has
been suggested that a drop in the UMOD urinary excretion is
specific only for cases with UMOD mutations.38 Our
investigations however showed that UMOD excretion was
significantly decreased in all but one family. Decreased
UMOD excretion could be considered as being secondary to
renal disease.39 While this might be true we favor the
explanation that our findings reflect and highlight the central
role of UMOD dysfunction in the development of common
FJHN/MCKD symptoms. This central role might be
attributed to the absence of proper UMOD function on the
plasma membrane and/or in the urine, as this factor seems to
be common to all the cases we have had the opportunity to
investigate. The absence of UMOD properly expressed on the
plasma membrane might result from different molecular
mechanisms such as reduced gene expression resulting from a
mutation of transcription factor as demonstrated in the case
of the HNF1-b mutation23,40 or in hypothyroidism,41 from
protein mistargeting, inability of the protein to be properly
GPI-anchored, from gradual gene expression silencing
resulting from aberrant developmental processes or from
aberrant cellular differentiation or proliferation.42
UAKD
Possible pathogenic mechanisms linking UMOD mutations
with characteristic disease symptoms have been discussed
recently.43 Hyperuricemia in UAKD results from the under-
excretion of uric acid. This feature usually appears at an early
age, well before the renal disease becomes apparent, so it
seems that hyperuricemia is somehow directly linked to
UMOD dysfunction. Our data from 36 UAKD patients show
positive correlation between urinary urate and urinary
UMOD concentrations (r¼ 0.62; Po0.0001), and this trend
has been observed also in 113 healthy individuals (r¼ 0.18;
Pp0.05). As minor UMOD expression has been found
also in proximal tubule cells,44 abnormal urate handling
and UMOD dysfunction linked through enhanced urate
reabsorption in the proximal tubule is a distinct possibility.
Another mechanism linked to hyperuricemia might be a
dysfunction of the UMOD containing water barrier on
the apical membrane of the loop of Henle cells, which
may result in nonspecific transcellular transport of urate in
this segment. Defects in the secretion, or enhanced
postsecretory reabsorption of urate linked to UMOD absence
in the distal convoluted tubule or collecting duct is yet
another possibility.
A common feature present in UAKD patients is also a loss
of urine concentrating efficiency.31,43 It has been suggested
that low urine osmolality may be attributed to dysregulation
of ion transport and electrolyte homeostasis. We hypothesize
that decreased urine concentrating efficiency might result
from the absence of released UMOD in both, the distal
convoluted tubule and the collecting duct. UMOD is
fundamental in cast formation, which takes place in the late
section of the distal tubules and the early section of the
collecting duct. Absence of UMOD may thus prevent cast
formation, enhance urine flow, impair water reabsorption,
and result in low urine osmolality. Abnormality in urine flow
and dysregulation of major distal tubule transporters in
UMOD/ mice45 supports this hypothesis.
To conclude, in our work we have shown that various
genetic defects and mechanisms hamper various steps in
UMOD biology, which probably leads to the development of
– – –+ –+ –+ –+ –+ –+ –+ –+ –+ – ?+
S C1 C2Cz1Cz2 T BE1 BE2 Cz3 Cz4 GB2 GB3 GB4 GB5 GB6 GB6GB8
a
b
Figure 6 | Qualitative analysis (SDS-PAGE and Western blot) of urinary UMOD in a single affected proband () and healthy individual
(þ ) from UAKD families showing the absence or significant reduction in urinary UMOD excretion. S: uromodulin standard isolated from
control urine, C: control urines, T: urine from patient with UMOD mutation after successful kidney transplantation ?: abnormal UMOD
processing that has been observed in several healthy individuals from various families.
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common FJHN/MCKD phenotype. This finding supports the
term of UAKD5,22 as the most appropriate for the FJHN/
MCKD designation. Given the frequency of urate abnorm-
alities, an alternative designation might be ‘familial urate–
uromodulin nephropathy’.
UMOD urinary excretion analysis with subsequent
UMOD sequencing is currently the primary diagnostic test
in UAKD patients. As suggested previously9 and clearly
documented here in family CZ5, this investigation should be
undertaken even in sporadic cases, in the absence of family
history as de novo mutations do appear. However, as the
protein has tendency to aggregate, a caution should be
exercised in interpretation of UMOD quantitative data.37,46
Qualitative Western blot analysis represents at least in our
hands the preferred method for extensive urinary UMOD
testing which has the potential to identify more UAKD
families without UMOD mutations. In these families, linkage
analysis to already defined loci or alternatively, whole genome
scans may be performed to confirm and narrow the existing
loci, or to reveal not yet identified UAKD loci. Identification
and characterization of other UAKD loci may help to clarify
the exact biological roles of UMOD, provide better diagnostic
techniques, and finally suggest potential therapeutic targets
and therapeutic approaches.36
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Figure 7 | Quantitative analysis (enzyme-linked immunosorbent assay) of urinary UMOD excretion. (a) Data plotted for the individual
linkage groups. 0: individuals of unknown status; 1: healthy individuals and 2: affected individuals from families with the UMOD mutation;
3: healthy individuals and 4: affected individuals from families linked to the UMOD candidate region on chromosome 16p11.2 but in which
no mutation in the UMOD gene has been detected; 5: healthy individuals and 6: affected individuals from families in which no linkage
to any of UAKD loci has been detected; 7: healthy individuals and 8: affected individuals from a family linked to UAKD loci on chromosome
1q41; 9: a patient with UMOD mutation after successful kidney transplantation; 10: controls. The number of individuals investigated in each of
the groups is indicated above corresponding columns. P-values (t-test) correspond to the comparisons between indicated group and controls;
***Po0.001. (b) The same results of quantitative urinary UMOD excretion plotted for individual families and showing reduction of UMOD
excretion in all families with an exception of CZ3. The number of individuals investigated in each group is indicated above the corresponding
columns; n 1 and n 2 denotes the number of healthy and affected individuals, respectively. Status 0 represents an unknown phenotype, status
1 and 2 represent healthy and affected individual, respectively. Status 3 represents a patient with UMOD mutation after successful kidney
transplantation. (c) Decreased UMOD excretion is present also in young patients with relatively preserved renal function. It is suggestive
that in the reported families the UMOD dysfunction precedes the onset of renal insufficiency. Black symbols denote patients from families with
UMOD mutations. Gray symbols denote patients from families with no UMOD mutations but showing linkage to UAKD-associated loci.
Black/white symbols denote patients from families in which no linkage to any of UAKD loci has been detected. Patients from family CZ3
showing normal UMOD excretion are not included in this figure. Control values of UMOD excretion are reported in Table 1 and its distribution is
shown in panels a and b.
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MATERIALS AND METHODS
Patients
In total, 19 families were enrolled in this study. Five families are
from the Czech Republic. Pedigrees of families CZ1, CZ2, and CZ3
have been reported (A, B, and C, respectively) previously;13 CZ4,
CZ5, and a single family from the USA (US1) are reported here for
the first time. Ten families are from Great Britain (GB1–GB10) and
two families are from Belgium (BE1, BE2).15 The single family is
from Finland (MCKD family 6).18
Biochemical investigations
Collected random spot urine samples were stored at 801C. Urine
total protein, creatinine, uric acid, magnesium, calcium, phosphate,
sodium, potassium, chloride, osmolality, and qualitative and quanti-
tative UMOD excretion were determined as previously described.22
Genotyping and linkage analysis
For MCKD/FJHN locus on chromosome 16p11.2, a set of 13
microsatellite markers D16S499–D16S501–D16S3056–D16S3041–
D16S3036–D16S3046–D16S403–D16S412–D16S3130–D16S417–D16-
S420–D16S3113–D16S401; for MCKD1 locus on chromosome 1q21,
a set of three microsatellite markers D1S1153–D1S2624–D1S2125;
and for UAKD locus on chromosome 1q41, a set of 11 markers
GATA31D05–D1S373–D1S2773–D1S245–D1S2703–D1S490–D1S1644–
D1S1656–D1S2649–D1S2850–D1S2670 were used. Genotyping and
linkage analysis were performed as previously described.15,22
UMOD gene analysis
Genomic organization, upstream promoter region sequence, and
genomic sequence of the UMOD gene were obtained using pairwise
BLASTN comparison of the UMOD cDNA sequence with the
corresponding genomic sequences. Primers for polymerase chain
reaction amplification and sequencing were designed using software
Oligo (National Biosciences, Plymouth, MN, USA). Genomic fragments
covering the promoter and all of the exons and intron–exon boundaries
were polymerase chain reaction amplified and sequenced as previously
described47 in a single proband and unaffected individual in each family.
UMOD cDNA expression constructs
UMOD cDNA was prepared from kidney cDNA using primers
UcDNA1U and UcDNA2L, cloned into pCR4-TOPO sequencing
vector (Invitrogen, Paisley, UK) and introduced into the Escherichia
coli TOP 10’F strain (Invitrogen, Paisley, UK). Mammalian
expression construct UcDNAwt/pCR3.1 was prepared by subcloning
of the UcDNAwt/pCR4-TOPO insert into pCR3.1 vector (Invitro-
gen, Paisley, UK) using EcoRI restriction sites. Mutated constructs
UcDNA229R/pCR3.1, UcDNA126R/pCR3.1, and UcDNA236L/
pCR3.1 were prepared by cloning of mutation bearing polymerase
chain reaction fragments, first into UcDNAwt/pCR4-TOPO con-
struct (UMODE4,5: 51980U and Cy5ex4,5-A primers, SacI a BstAPI
restriction sites), and then into pCR3.1 vector (Invitrogen, Paisley,
UK), using EcoRI restriction sites as described above.
Mutated constructs UcDNA32Y/pCR3.1, UcDNA273F/pCR3.1,
and UcDNA317Y/pCR3.1 were prepared by site-directed mutagen-
esis of UcDNAwt/pCR3.1 construct (GeneTailor kit, Invitrogen,
Paisley, UK). All the primer sequences are available upon request.
Cell culture and transfection experiments
AtT-20 pituitary cells were maintained in DMEM high glucose
medium supplemented with 10% (vol/vol) fetal calf serum, 100 U/
ml penicillin G, and 100mg/ml streptomycin sulfate (PAA
Laboratories GmbH, Pashing, Austria). Cells were used at 80%
confluence. Transfection was carried out with 4 mg of DNA using
Lipofectamine 2000TM (Invitrogen, Paisley, UK).
Flow cytometry
AtT-20 cells were seeded in six-well tissue culture plates (BD Falcon,
Palo Alto, CA, USA). Following 24-h incubation, the cells were
transfected and harvested at the indicated time after the transfection.
2 105 cells were washed, stained for 30 min with 1.5mg of fluorescein
isothiocyanate-labeled (Fluorescent Labelling Kit, Roche, Prague, Czech
Republic) anti-UMOD – rabbit polyclonal IgG (Biogenesis, Pool, UK),
washed and fixed in 2% paraformaldehyde. Fluorescence was measured
using FACSCalibur flow cytometer and analyzed using the Cell Quest
software version 3.3 (Becton Dickinson, San Jose, CA, USA). Cell-
surface expression of UMOD was quantified as the geomean of the
fluorescence of gated fluorescein isothiocyanate-positive cells.
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Figure 8 | Immunohistochemical analysis of UMOD and MUC1
in kidney biopsies. In control tissue, (a) UMOD shows diffuse
cytoplasmic staining with maximal intensity on the apical membranes
and (b) MUC1 is expressed almost exclusively on the apical
membrane of the cells of the ascending limb of the loop of Henle.
The tissue of patient with the UMOD mutation shows (c) massive
intracellular accumulation of UMOD and (d) abundant MUC1
presence with strong uniform intracellular positivity. In a case from
family GB3 linked to the UMOD region on chromosome 16p11.2
but in which no UMOD mutation has been found, shows (e) UMOD
to be present in hyaline casts with low intracellular positivity and
(f) normal or variable intracellular increase of MUC1 exceeding this
of UMOD. A case from family GB6, in which no linkage to any of
the UAKD loci has been found shows (g) an irregular pattern of
UMOD staining and (h) normal or close to normal expression
of MUC1. In three patients from a family linked to 1q41, (i) UMOD
and (j) MUC1 expression is strongly reduced and both proteins
are present in the form of tiny intracellular granules.
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Figure 9 | Ultrastructural changes in renal tubules compatible with the ascending loop of Henle prepared from the kidney biopsy from
a patient with the M229R UMOD mutation. Individual cells are labeled with Roman numerals, ER: endoplasmic reticulum, BM: basal
membranes, M: mitochondria, *: distended basal invaginations. (a) Considerably distended basal invagination of many tubules projected
into the cell interior. (b) Thickened and partly multilayered basement membrane with increase in the number of mitochondria, which were
generally rich in the inner membrane system. Cilia is shown by arrow and enlarged in the insert. (c, d) Abundant slender rough ER cisternae
arranged in slightly curved or whirled stacks present in flat tubular epithelia and in those exhibiting expansion of ER with amorphous
moderately dense content ranging from slight to massive distension. (e) Detail of distension of the basal cisternae with an arrow pointing to
their communication with the extracellular space. (f) Detail of the ER storage areas either bulging into the apical pole luminally or facing the
basolateral pole.
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SDS-PAGE and Western blotting analysis
Harvested cells were resuspended in phosphate-buffered saline
containing Protease inhibitor coctail (Sigma, Prague, Czech Republic)
and sonicated. UMOD was detected as described previously.22
Deglycosylation experiments
Deglycosylation experiments were performed on cell lyzates using
the GlycoProTM enzymatic deglycosylation kit (ProZyme Inc.,
San Leandro, CA, USA). Deglycosylated products were analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blot as described above.
Immunofluorescence
For immunofluorescence, 6.5 104 of AtT-20 cells were grown on
70 mm2 glass chamber slides (BD Falcon – 4Chamber Polystyrene
Vessel Tissue Culture Treated Glass Slide) for 24 h and transfected as
described above. At 18 h after the transfection, the cells were fixed
with 100% methanol at 201C, washed, blocked with 5% FCS
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Figure 10 | Cellular localization of the UMOD in the renal biopsy tissue from control (rows a–d, m–p), from patient with the M229R
UMOD mutation (rows e–h, q–t), and from patient with no UMOD mutation (rows i–l, u–x). In control, (a) UMOD is clearly present on apical
membrane of the ascending limb of the loop of Henle cells as is the plasma membrane marker (b) MUC1. In patient with the M229R UMOD
mutation, both (e) UMOD and (f) MUC1 show diffuse intracellular staining pattern suggesting decreased efficiency in targeting of membrane
cargo proteins into plasma membrane. In patient with no UMOD mutation, (i) UMOD shows diffuse intracellular staining pattern as in the case
with UMOD mutation, but (j) MUC1 expression is clearly normal. (c, g, k) Merged fluorescence signals of UMOD (red) and MUC1 (green), and
(d, h, l) colocalization maps employing overlap coefficient values are shown for control, patient with the M229R UMOD mutation and patient
with no UMOD mutation, respectively. In patient with the M229R UMOD mutation, the intracellular localization of (q) UMOD was assigned
almost exclusively into (r) ER as seen by fluorescence signal merge of UMOD (red) with (s) ER marker PDI (green) and the corresponding
(t) colocalization map. The degree of UMOD signal retention in ER is demonstrated by the overlap coefficient value (note the scale of the
lookup tables, compare to (p), and see the massive ER storage in Figure 9). In patient with no UMOD mutation, the intracellular localization
of (u) UMOD could not be attributed to (v) ER, as seen by fluorescence signal merge of UMOD (red) with (w) ER marker PDI (green) and the
(x) corresponding colocalization map. In this case, the defect seems to affect either proper UMOD internalization into plasma
membrane or inefficient targeting and/or processing of UMOD in ER (compare colocalization maps for (p) control and (x) patient).
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and incubated for 1 h at 371C with primary antibodies: rabbit
Anti-Human THP polyclonal antibodies (Biogenesis, Poole, UK) or
Anti-Human THP mouse IgG2b monoclonal antibodies (Cedarlane,
Hornby, Ontario, Canada) for UMOD detection; anti-PDI – mouse
monoclonal IgG1 (Stressgen, San Diego, CA, USA) for ER
localization; anti-GS28 mouse monoclonal IgG (Stressgen, San
Diego, CA, USA) for Golgi localization, and anti-pan Cadherin
rabbit polyclonal IgG (Abcam, Cambridge, UK) for plasma
membrane localization. For fluorescence detection, secondary
antibodies – Alexa 568 goat anti-rabbit IgG and Alexa 488 goat
anti-mouse IgG (Molecular Probes, Invitrogen, Paisley, UK) were
used. Prepared slides were mounted in fluorescence mounting
medium Immu-Mount (Shandon Lipshaw, Pittsburgh, PA, USA)
and analyzed by confocal microscopy.
Image acquisition and analysis
XYZ images sampled according to Nyquist criterion were acquired
using Nikon Eclipse E800 microscope equipped with C1 confocal
head, Nikon PlanApo objective (60X, N.A.1.40), 488 and 543 nm
laser lines, and 515715 and 590715 nm band pass filters. Images
were deconvolved using classic maximum likelihood restoration
algorithm in the Huygens Professional Software (SVI, Hilversum,
The Netherlands).48 The colocalization maps employing single pixel
overlap coefficient values ranging from 0 to 149 were created in the
Huygens Professional Software. The resulting overlap coefficient
values are presented as the pseudocolor whose scale is shown in
corresponding lookup tables.
Immunohistochemistry studies
Formaldehyde- or ethanol-fixed kidney samples were analyzed.
Immunodetection of UMOD was performed as previously
described.22 Immunodetection of mucine 1 (MUC1, epithelial
membrane antigen) was carried out using anti-MUC1 monoclonal
antibody (DAKO, Carpinteria, CA, USA).
Electron microscopy
Renal biopsy specimen was fixed with 4% paraformaldehyde (PFA)
in 0.1 M phosphate buffer for 30 min and by buffered 1% OsO4 for
2 h, dehydrated and embedded into Epon. Thin sections were
double contrasted with uranyl acetate and lead nitrate. Photographs
were obtained on a TESLA 500 electron microscope.
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